5 Low-Beta Stocks To Tackle Coronavirus-Led Market Volatility
Zacks Investment Research | Mar 18, 2020 09:49PM ET
The coronavirus pandemic has now spread across 176 countries, infecting approximately 221,568 people worldwide. With no cure or vaccine found yet, countries are going under lockdowns and governments are requesting people to practice social distancing. This is also impacting businesses as they are constantly facing supply chain disruption. and many had to shut doors for undisclosed period to stop the infection from spreading.
Equity markets are in a turmoil as the coronavirus-driven panic resulted in rapid sell-off, in turn, pushing benchmarks to record low levels. In fact, the Federal Reserve’s monetary easing did little to improve investors’ sentiments. In such a turbulent state, low-beta stocks have recorded strong gain since these are less volatile than the broader market and investors can bank on them to keep their money safe.
Why Low-beta Stocks?
In times like these, when there is high global risk and uncertainty, investors looking for growth stocks can consider buying "low beta" stocks. What is beta? Beta is a measure of volatility of a particular stock that compares its historic price swings to those in the market as a whole.
When the stock has beta of less than 1.0, it indicates that the stock tends to go up and down less than the market, here the S&P 500 Index. Likewise, if the stock’s beta is greater than 1.0, then it is more volatile compared to the market.
5 Stocks to Buy Now!
Given the volatility in equity market we have shortlisted five stocks that have beta in the range of 0 to 1. What’s more? These stocks have seen a positiveprice movement over the past month and carry a Zacks Rank #1 (Strong Buy) or #2 (Buy).
The first one on our list is biopharmaceutical company, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) . This Zacks Rank #1 company’s expected earnings growth rate for the current quarter is 41.4% against the Zacks Food - Miscellaneous industry’s projected earnings growth of 4%. The Zacks Consensus Estimate for the company’s current-year earnings has been revised 2.8% upward over the past 60 days.
Get The News You Want
Shares of Regeneron Pharmaceuticals, Novavax, Cogent Communications, The Clorox Company and Campbell Soup Company have risen 21%, 34%, 12.4%, 15.8% and 5.6%, respectively in the past 30 days.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.